Dabigatran for Anticoagulation in Atrial Fibrillation – Early Clinical Experience in a Hospital Population and Comparison to Trial Data - 16/01/13
Résumé |
Background |
Dabigatran is a recently introduced direct thrombin inhibitor licensed for use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation. Our prospective observational study aimed to assess the adverse effects, tolerability and patient satisfaction of dabigatran therapy in a hospital-practice population.
Methods |
Patients starting dabigatran, after its release in June 2011, were identified from clinical practice at two Wellington hospitals, New Zealand. Baseline characteristics were recorded from the clinical record and a telephone interview was performed in January 2012. Primary outcomes included adverse events, adherence, and satisfaction with treatment.
Results |
Data were available for 70 patients: median age 71.9 years (IQR 62.7–79.0), weight 80kg (IQR 71–95), CHA2DS2-VASc score 3 (IQR 2–4). Seventy-one percent of patients reported adverse events although the majority were minor. Twenty-four percent (16/70) had discontinued treatment with dabigatran; four due to predominantly gastrointestinal side effects, three due to bleeding (one severe), one as a result of adverse media coverage with the remainder comprising planned treatment discontinuation and undetermined. In total, 29% reported bleeding events, predominantly minor bleeding and bruising. There were no cerebrovascular events. Nineteen percent reported some difficulty with twice daily dosing adherence with 13 of 70 reporting missed doses. Seventy-seven percent reported treatment satisfaction and 79% of those previously treated with warfarin preferred dabigatran.
Conclusion |
In this population our study demonstrates a discontinuation rate of 10% due to side effects of dabigatran, similar to the rate reported in RE-LY. The majority of patients are satisfied with their treatment and preferred dabigatran to warfarin, mainly due to the reduced requirement for blood testing.
Le texte complet de cet article est disponible en PDF.Keywords : Dabigatran, Atrial fibrillation, Cerebrovascular accident, Warfarin, Dyspepsia, Adverse effects, Bleeding, Adherence, Patient satisfaction, Prospective, RE-LY, MACE
Plan
Vol 22 - N° 1
P. 50-55 - janvier 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?